Physiology-Based Revascularization Decisions and Improved Clinical Outcomes following Percutaneous Coronary Interventions

Richard G. Bach

doi:10.1001/jama.2020.22998

Physiology-Based Revascularization Decisions and Improved Clinical Outcomes following Percutaneous Coronary Interventions

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	2377-2380
Number of pages	4
Journal	JAMA - Journal of the American Medical Association
Volume	324
Issue number	23
DOIs	https://doi.org/10.1001/jama.2020.22998
State	Published - Dec 15 2020

Access to Document

10.1001/jama.2020.22998

Cite this

@article{c0afe73cdb24422fb23c3b461cee89b2,

title = "Physiology-Based Revascularization Decisions and Improved Clinical Outcomes following Percutaneous Coronary Interventions",

author = "Bach, {Richard G.}",

note = "Funding Information: receiving consulting fees from Alcon, Allergan, Bayer, and Novartis; and receiving grants from Santen. Dr Chakravarthy reported being the chair of the data and safety monitoring committee for 2 Bayer trials (Photon and Pulsar); receiving consulting fees from IVERIC bio, Roche, and Apellis; and receiving speaker fees from Alimera and Novartis. Dr Wong reported receiving consulting fees from and serving on advisory boards for Allergan, Bayer, Boehringer-Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, and Samsung. No other disclosures were reported.",

year = "2020",

month = dec,

day = "15",

doi = "10.1001/jama.2020.22998",

language = "English",

volume = "324",

pages = "2377--2380",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

number = "23",

}

TY - JOUR

T1 - Physiology-Based Revascularization Decisions and Improved Clinical Outcomes following Percutaneous Coronary Interventions

AU - Bach, Richard G.

N1 - Funding Information: receiving consulting fees from Alcon, Allergan, Bayer, and Novartis; and receiving grants from Santen. Dr Chakravarthy reported being the chair of the data and safety monitoring committee for 2 Bayer trials (Photon and Pulsar); receiving consulting fees from IVERIC bio, Roche, and Apellis; and receiving speaker fees from Alimera and Novartis. Dr Wong reported receiving consulting fees from and serving on advisory boards for Allergan, Bayer, Boehringer-Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche, and Samsung. No other disclosures were reported.

PY - 2020/12/15

Y1 - 2020/12/15

UR - http://www.scopus.com/inward/record.url?scp=85096109415&partnerID=8YFLogxK

U2 - 10.1001/jama.2020.22998

DO - 10.1001/jama.2020.22998

M3 - Editorial

C2 - 33185653

AN - SCOPUS:85096109415

SN - 0098-7484

VL - 324

SP - 2377

EP - 2380

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 23

ER -

Physiology-Based Revascularization Decisions and Improved Clinical Outcomes following Percutaneous Coronary Interventions

Access to Document

Other files and links

Cite this